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Phaeochromocytomas are uncommon tumours which 
are important because of their life-threatening 
metabolic effects. Surgical treatment is usually 
highly successful, but unfortunately approximately 
one third of cases are not diagnosed in life and 
nearly half of the deaths in undiagnosed patients are 
associated with general anaesthesia for some other 
surgical procedure. 
The word phaechromocytoma is derived from the 
Greek phaeos meaning dusky and chromos mean- 
ing colour because the tumour cells of the adrenal 
medulla stain dark brown with chromium salts. The 
first accurate clinical description linked to autopsy 
findings was by Frhkel  of Freiburg, Germany, in 
1886. The first diagnosis in life was achieved in 
Paris in 1922 by Labb6, Tinel and Doumer, but the 
patient died without surgery being attempted. The 
first successful surgical operations were performed 
independently by Roux in Lausanne, Switzerland, 
and Mayo in Rochester, Minnesota, USA in 1926.3 
The incidence of haeochromocytomas is ap- 
tumours are often referred to as the ' 10% tumours' 
because approximately 1O0/o are bilateral, or extra- 
adrenal, or malignant, or occur in children or the 
multiple endocrine neoplasia type I1 syndrome. 
The symptoms are usually intermittent and may 
vary greatly in individual patients according to the 
relative secretion of adrenaline and noradrenaline4 
and probably also dopamine.' Hypertension is the 
most consistent finding with about half the patients 
having paroxysmal hypertension and half having 
sustained hypertension. Only recently have mem- 
bers of multiple endocrine neoplasia type I1 fami- 
lies been discovered to have phaeochromocytomas 
at a stage before even paroxysms of hypertension 
have been noted. It is probably not cost-effective to 
screen all patients with only hypertension because 
less than 1 %  will prove to have phaeochromo- 
cytomas.' The combination of hypertension and 
proximately 1.5-2/10 t population per year.'*2 The 
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any one of the additional features noted below 
should lead to measurement of catecholamine 
levels. Hypertension, plus all three of the other 
'classic' symptoms of headache, sweating. or pal- 
pitations, has a sensitivity and specificity of 
approximately 90% for phaeochromocytoma in a 
patient with sustained hypertension.6 Hypertension 
which is difficult to control or occurring in chil- 
dren, young adults, pregnancy, or in association 
with glucose intolerance, neurofibromatosis or 
medullary carcinoma of the thyroid should also lead 
to investigation. Cardiovascular crises occurring 
under anaesthesia, in particular hypertension, tachy- 
arrhythnuas, pulmonary oedema, or shock should 
always raise suspicion of phaeochromocytorna. 
Diagnosis is achieved by measurement of plasma 
and/or urinary catecholamines and their metabo- 
lites. Dopamine is occasionally an important 
secretory product, particularly of malignant 
turnours,' but it is sufficient in nearly all cases to 
measure adrenaline and noradrenaline and their 
metabolites.' There is a continuing controversy 
over the choice of the most appropriate test al- 
though there is more consensus that high pressure 
liquid chromotographic methods are more sensitive 
and specific than earlier techniques.*39 However, 
fluorometric urinary catecholamine analysis is still 
widely used in clinical laboratories. A number of 
commonly used drugs including a-methyl-dopa 
interfere with fluorometric analysis and it is 
imperative to cease them several weeks before test- 
ing to avoid false positive results. These drugs, 
however, do not interfere with radio-enzymatic 
assays for plasma catecholamines. It would be 
advantageous from a cost-efficiency perspective to 
be able to rely on a single test, but this is not 
possible. Although there are advocates for plasma 
catecholamines and the urinary metabolites meta- 
nephrine and vanillylmandelic acid, no test is suffi- 
ciently reliable to be relied upon e x c l ~ s i v e l y . ' ~ ' ~  In 
a clinical situation where the suspicion of phaeo- 
chromocytoma is high, a single negative test result 
should not be accepted and repeated testing of 
several catecholamines would be appropriate. Pro- 
vocative tests should not be performed but suppres- 
sion tests using clonidine may be useful in patients 
with only slightly elevated plasma catecholamine 
levels. 9*'0 
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Imaging investigations are instituted after the 
diagnosis has been firmly established biochemical- 
ly. Computerized tomographic (CT) scanning has a 
sensitivity of approximately 90% in detecting intra- 
adrenal phaeochromocytomas. I' Magnetic reson- 
ance imaging is probably no more sensitive than 
CT, but is proving to be more specific because it 
can distinguish phaeochromocytomas from other 
adrenal masses such as cortical neoplasms and 
metastases.I4.l5 Malignant phaeochromocytomas, 
however, have the same magnetic resonance 
appearance as benign phaeochromocytomas. I s  Nei- 
ther technique, when used routinely, is as reliable 
in detecting extra-adrenal phaeochromocytomas 
unless directed at a specific anatomical area. 
"'I-rn-iodobenzylguanidine ( 13'I-MIBG) scintig- 
raphy was introduced at the University of Michigan 
Hospitals in 1980 and has since been used there in 
evaluating over 200 patients with proven phaeo- 
chromocytoma. This technique is currently being 
used in major hospitals around the world. It has a 
similar overall sensitivity to that of CT but has 
greater specificity and is also superior to CT in the 
detection of phaeochromocytomas in extra-adrenal 
sites. I3'I-MIBG is also particularly useful in iden- 
tifying malignant metastases in sites such as bone, 
liver, and lungs. '' I3'I-MIBG has located medias- 
tinal phaeochromocytomas which escaped detec- 
tion by previous investigations but which were then 
able to have their exact anatomical relationships 
further defined by dynamic contrasted CT imag- 
ing.17 At the University of Michigan, 13 patients 
with middle mediastinal phaeochromocytoma have 
been identified initially by '3'I-MIBG scintigraphy. 
CT and '"'I-MIBG scans are complementary and 
should be done in all cases pre-operatively because 
together they will correctly locate at least 95% of 
tumours. IX The identification of an extra-adrenal 
phaeochromocytoma and/or the finding of normal 
plasma adrenaline levels when other cate- 
cholamines are elevated should raise the suspicion 
that the tumour may be malignant.7 Invasive inves- 
tigations such as arteriography or adrenal venous 
sampling should now rarely, if ever, be necessary 
for the location of a phaeochromocytoma. Since the 
introduction of 13'I-MIBG, neither technique has 
been used by the authors. 
Pre-operative preparation with a-adrenergic re- 
ceptor blockade is essential and is one of the main 
reasons for the relative safety of surgery on phaeo- 
chromocytomas in the modern era. Induction of 
general anaesthesia and manipulation of the tumour 
provoke the release of large amounts of ca- 
techolamines and prior receptor blockade is very 
important. Most patients have some reduction of 
intravascular volume and a blockade for 7 to 10 days 
allows volume re-expansion. The most commonly 
used drug 'is phenoxybenzamine which is given 
orally in gradually increasing amounts, if necessary 
up to 300 mg day, until postural hypotension devel- 
ops. After a-blockade is established, a P-blocking 
agent such as propranolol may be added for the last 
few days pre-operatively. The administration of a 
@-blocker is not always necessary but P-blockers 
are useful if there is tachycardia, particularly during 
the operation itself. The use of P-blockers is also 
recommended in patients whose catecholamine pro- 
file indicates an excessive secretion of adrenaline. 
In other rare circumstances, drugs such as the a- 
blocker phentolamine or the enzyme inhibitor a- 
methyl-p-tyrosine may be helpful .4 
During surgery, monitoring of intra-arterial 
blood pressure is essential and monitoring of cen- 
tral venous pressure is also advisable. Although 
some have advocated routine use of a Swan-Ganz 
catheter for measurement of pulmonary wedge 
pressure, its insertion may provoke cardiac arryth- 
mias in the sensitized myocardium. It is recorn- 
mended, therefore, that it should be used, with 
caution, in patients who have been in congestive 
heart failure. Blood pressure fluctuations should be 
expected even in a well-prepared patient. The a- 
and P-blocking agents previously mentioned may 
be used to manage blood pressure and arrhythmias 
during surgery, but for the control of hypertension 
many anaesthetists prefer to use rapidly acting 
direct vasodilating agents such as sodiuni nitroprus- 
side or adenosine. 192" Intravenous nitroprusside 
has been used routinely when the systolic blood 
pressure exceeds 160 mmHg, with titration of the 
rate of infusion to control the blood pressure at this 
level or lower. After removal of the tumour there 
may be a substantial increase in the intravascular 
capacity and this is better managed by intravenous 
fluid replacement rather than by vasopressor drugs. 
Rarely, in the well-prepared patient, an intravenous 
infusion of noradrenaline may be required while 
volume is being restored. 
The operative approach will be influenced by the 
pre-operative imaging investigations. For intra- 
abdominal phaeochromocytomas a thorough 
laparotomy through an anterior approach is recom- 
mended to allow exploration of both adrenal glands 
and exploration for extra-adrenal phaeochronio- 
cytomas, particularly along the aorta and in the 
renal hila. Even after CT and '"I-MIBG have been 
performed, some tumours will not have been 
detected and such patients will not be cured unless a 
complete laparotomy is performed.2' Palpation of 
even small extra-adrenal tumours will cause blood 
pressure fluctuations despite pre-operative a- 
blockade, and the withholding of such preparation, 
as advocated by some, would subject the patient to 
a preventable increased risk of intra-operative 
hypertensive crisis. 
The tumours should be approached cautiously 
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and handling of the tumour itself kept to a mini- 
mum. lnterruption of the major effluent vein or 
veins is desirable at an early stage of dissection to 
reduce catecholamine discharge into the circula- 
tion. Access to the right adrenal is achieved by 
reflecting the duodenum and head of pancreas to 
the left after using Kocher's manoeuvre and mobi- 
lizing the inferior vena cava. There is often a short 
vein between the inferior vena cava and the right 
lobe of the liver and, if present, it should be divided 
before attempting to dissect around the phaeo- 
chromocytoma. Access to the left adrenal is 
obtained either via the lesser sac or inferior to the 
transverse mesocolon and reflection of the pancreas 
superiorly. This approach leads directly to the left 
adrenal and minimizes the risk of splenic injury. 
The long left adrenal vein, draining into the left 
renal vein, is easily identified and secured before 
any manipulation of the tumour is required. 
Postoperatively patients should be followed up 
for life with at least annual blood ressure measure- 
ment and catecholamine studies.42 At the Univer- 
sity of Michigan, follow-up I3II-MIBG scans are 
done in any patient who has symptoms suggestive 
of recurrence. In several patients, tumour recur- 
rence, or an occult tumour, has been detected in the 
presence of normal catecholamine levels. Recur- 
rence may happen if benign tumour cells were seed- 
ed by rupture of the tumour at the first operation, or 
if the tumour was malignant, and of course a new 
primary tumour may develop in the opposite adre- 
nal gland or elsewhere. The diagnosis of malig- 
nancy in the absence of metastases cannot be made 
on usual histological criteria because nuclear pheo- 
morphism, giant cells, frequent mitotic figures, and 
capsular invasion may all occur in tumours which 
subsequently follow a benign course. Recently, 
measurement of nuclear DNA ploidy has shown 
promise of providing useful additional prognostic 
information in phaeochromocytomas. 23 
Malignant phaeochromocytomas are best treated 
surgically if the tissue is resectable. External beam 
radiotherapy is sometimes helpful for unresectable 
tumours, particularly in bone, when pain relief is 
needed. Its use in other areas is limited because of 
the relative radioresistance of the tumours which 
require approximately 6000-9000 rad for effect. 
Widespread systemic metastases may be managed 
with high therapeutic doses of 1311-MIBG17 al- 
though only about one third of metastases take up 
sufficient isotope to achieve adequate tumour irra- 
diation. I t  is currently estimated that 9ooo rad is 
necessary to demonstrate reduction in tumour size 
and decreased secretion of catecholamines, and this 
would usually require repeated doses of 1311-MIBG. 
Chemotherapy and interferon are other options 
which are currently undergoing evaluation with 
some partial tumour responses being noted. For 
control of symptoms, phenoxybenzamine and a- 
methyl-p-tyrosine are particularly useful. I 6  It 
should be realized that metastatic phaeochromo- 
cytoma may be relatively slow growing and some 
patients survive many years when their blood pres- 
sure is controlled with adequate therapy. Because 
of the inability to determine whether a phaeo- 
chromocytoma is benign or malignant on standard 
histopathologic criteria, and the propensity for bone 
metastases to remain occult for long periods of time, 
careful life-time follow-up is further emphasized. 
In summary, phaeochromocytomas produce a 
variety of symptoms and a high index of suspicion 
is necessary before the diagnosis is likely to be 
made. In the hands of an experienced clinical team, 
the combination of accurate imaging investigations, 
careful pre-operative adrenergic blockade, expert 
anaesthesia, and intelligent surgery should lead to a 
successful outcome in most patients. 
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